Boundless Bio
cancer most common high copy number amplifications frequently occur on when they do it is associated with worse survival | Boundless Bio
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2024
Slide
17 of 51
Related slides by other companies
Genprex
Investor Presentation
November 2024
lung cancer by the numbers | Genprex
AstraZeneca
Investor Day
June 2022
her low breast cancer visible but | AstraZeneca
Genelux
Investor Presentation
December 2023
completed phase tested primed heavily patients with platinum resistant or platinum refractory ovarian cancer published in jama oncology link | Genelux
Electronic Arts
Results
February 2025
numbers above may not foot due to rounding and calculation methodologies constant currency reconciliation net bookings guidance low high low high | Electronic Arts
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights